Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

Posted: December 17, 2020 at 7:55 am

GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG

Follow this link:
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

Related Posts